Literature DB >> 23442062

Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant.

Celalettin Eroglu1, Cigdem Pala, Leylagül Kaynar, Kadir Yaray, M Tarkan Aksozen, Mehmet Bankir, Gökmen Zararsız, Okan Orhan, Mete Gündog, Oguz G Yıldız, Bülent Eser, Mustafa Cetin, Ali Unal.   

Abstract

Conditioning regimens used during stem cell transplant provide prolonged control or cure of the disease in patients with acute lymphoblastic leukemia (ALL). In this study, we present a comparison of treatment results for 95 patients with ALL who underwent allogeneic hematopoietic stem cell transplant (AHSCT) with total body irradiation plus cyclophosphamide (TBI + Cy) or busulfan plus cyclophosphamide (Bu + Cy) as conditioning regimen. Median age was 25 (range: 9-54) years. Median follow-up was 24 (range: 3-107) months. Median overall survival (OS) was found to be 29 months. Median event-free survival (EFS) was 9 months. Median OS was 37 months in the TBI + Cy arm, while it was 12 months in the Bu + Cy arm, suggesting a significant advantage favoring the TBI + Cy arm (p = 0.003). Median EFS was 13 months in the TBI + Cy arm, while it was 4 months in the Bu + Cy arm, indicating a significant difference (p = 0.006). In univariate and multivariate analysis, it was found that high OS and EFS were significantly correlated with TBI + Cy conditioning regimen and lack of transplant-related mortality (p < 0.05). The TBI + Cy conditioning regimen was found to be superior to the Bu + Cy regimen in patients with ALL undergoing AHSCT regarding both OS and EFS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23442062     DOI: 10.3109/10428194.2013.779691

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Sebastian Giebel; Myriam Labopin; Gerard Socié; Dietrich Beelen; Paul Browne; Liisa Volin; Slawomira Kyrcz-Krzemien; Ibrahim Yakoub-Agha; Mahmoud Aljurf; Depei Wu; Mauricette Michallet; Renate Arnold; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2016-09-29       Impact factor: 9.941

2.  Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.

Authors:  Omer Jamy; Sankalp Arora; Ruby Meredith; Donna Salzman; Antonio Di Stasi; Kentaro Minagawa; Shin Mineishi; Ayman Saad
Journal:  Bone Marrow Transplant       Date:  2022-07-09       Impact factor: 5.174

3.  Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.

Authors:  Anne Banet; Ali Bazarbachi; Myriam Labopin; Nicolas Stocker; Rémy Duléry; Florent Malard; Zoé Van de Wyngaert; Alexis Genthon; Mara Memoli; Ollivier Legrand; Agnes Bonnin; Tounes Ledraa; Ramdane Belhocine; Simona Sestili; Jean El-Cheikh; Mohamad Mohty; Eolia Brissot
Journal:  Bone Marrow Transplant       Date:  2022-10-12       Impact factor: 5.174

4.  Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.

Authors:  X Cahu; M Labopin; S Giebel; M Aljurf; S Kyrcz-Krzemien; G Socié; M Eder; F Bonifazi; D Bunjes; S Vigouroux; M Michallet; M Stelljes; T Zuckerman; J Finke; J Passweg; I Yakoub-Agha; D Niederwieser; G Sucak; H Sengeløv; E Polge; A Nagler; J Esteve; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-11-30       Impact factor: 5.483

5.  Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party.

Authors:  Mohamad Mohty; Arnon Nagler; Eolia Brissot; Myriam Labopin; Domenico Russo; Sonja Martin; Christoph Schmid; Bertram Glass; Ron Ram; Zubeyde Nur Ozkurt; Jakob Passweg; Joan Hendrik Veelken; Donald Bunjes; Jane Apperley; Sebastian Giebel
Journal:  Bone Marrow Transplant       Date:  2020-03-17       Impact factor: 5.483

6.  Once-a-day fractionated total-body irradiation: A regimen tailored to local logistics in allogeneic stem cell transplantation for acute lymphoblastic leukemia.

Authors:  Nour Ben Abdeljelil; Saloua Ladeb; Talel Dahmani; Lotfi Kochbati; Amel Lakhal; Rym El Fatmi; Lamia Torjemane; Dorra Belloumi; Mounir Besbes; Farouk El Benna; Chiraz Nasr Ben Ammar; Tarek Ben Othman
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-28

7.  Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.

Authors:  C Greil; M Engelhardt; G Ihorst; J Duque-Afonso; K Shoumariyeh; H Bertz; R Marks; R Zeiser; J Duyster; J Finke; R Wäsch
Journal:  Bone Marrow Transplant       Date:  2020-10-31       Impact factor: 5.483

8.  Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation.

Authors:  Ibrahim El-Serafi; Manuchehr Abedi-Valugerdi; Zuzana Potácová; Parvaneh Afsharian; Jonas Mattsson; Ali Moshfegh; Moustapha Hassan
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

9.  Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.

Authors:  Yu-Hung Wang; Feng-Ming Tien; Cheng-Hong Tsai; Huai-Hsuan Huang; Jia-Hau Liu; Xiu-Wen Liao; Jih-Luh Tang; Ming Yao; Bor-Sheng Ko
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.